Depomed, Inc. Selects inVentiv Health to Provide Sales Team for Gralise(TM)
June 20, 2011 07:00 ET
|
Depomed, Inc.
BURLINGTON, Mass. and MENLO PARK, Calif., June 20, 2011 (GLOBE NEWSWIRE) -- inVentiv Health, offering best-in-class clinical, consulting and commercial services to the healthcare industry, and...
New Analyses of Safety and Efficacy Data of Depomed's Gralise(TM) to be Presented at the 63rd Annual Meeting of the American Academy of Neurology
April 12, 2011 17:26 ET
|
Depomed, Inc.
MENLO PARK, Calif., April 12, 2011 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that two new analyses of phase 3 clinical data of Gralise™ (gabapentin), a once-daily evening...
Depomed Reports Fourth Quarter and Year-End 2010 Financial Results
March 03, 2011 16:05 ET
|
Depomed, Inc.
MENLO PARK, Calif., March 3, 2011 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today reported financial results for the fourth quarter and year ended December 31, 2010.
"We are pleased to report...
Depomed Completes Enrollment of Breeze 3 Phase 3 Clinical Trial for Non-Hormonal Treatment in Menopausal Hot Flashes
March 03, 2011 04:00 ET
|
Depomed, Inc.
MENLO PARK, Calif., March 3, 2011 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) announced today that it has completed enrollment of Breeze 3, the company's pivotal Phase 3 clinical trial evaluating...
Depomed Announces US Food and Drug Administration Approval of GRALISE(TM) (gabapentin) Once-Daily Tablets for Treatment of Post-Herpetic Neuralgia
January 28, 2011 19:30 ET
|
Depomed, Inc.
MENLO PARK, Calif., Jan. 28, 2011 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that US FDA has approved GRALISE™ (gabapentin) Tablets for once-daily treatment of post-herpetic...
Depomed Will Engage in Mediation to Resolve Dispute With Abbott; Comments on DM-1796 Regulatory Status and Orphan Drug Designation
January 18, 2011 16:05 ET
|
Depomed, Inc.
MENLO PARK, Calif., Jan. 18, 2011 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that it will engage in a mediation process with Abbott Products, Inc., regarding Abbott's...
Depomed to Present at the UBS Global Life Sciences Conference and the Fifth Annual JMP Securities Healthcare Conference
September 17, 2010 17:59 ET
|
Depomed, Inc.
MENLO PARK, Calif., Sept. 17, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) announced today that its president and chief executive officer, Carl A. Pelzel will be presenting at the UBS Global...
Depomed to Present at the Rodman & Renshaw 12th Annual Healthcare Conference
September 09, 2010 07:00 ET
|
Depomed, Inc.
MENLO PARK, Calif., Sept. 9, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) announced today that its president and chief executive officer, Carl A. Pelzel will be presenting at the Rodman &...
Depomed Reaches SPA Agreement With FDA for Phase 3 Hot Flash Trial
August 11, 2010 07:00 ET
|
Depomed, Inc.
MENLO PARK, Calif., Aug. 11, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special...
Depomed Licenses GLUMETZA(R) Data and Acuform(R) Technology
August 05, 2010 16:40 ET
|
Depomed, Inc.
MENLO PARK, Calif., Aug. 5, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that Janssen Pharmaceutica N.V. has licensed worldwide rights to Depomed's Acuform® gastric...